Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
13
DSNKY Quote, Financials, Valuation and Earnings
Last price:
$21.90
Seasonality move
:
2.54%
Day range:
$21.41 - $22.74
52-week range:
$20.92 - $31.48
Dividend yield:
0%
P/E ratio:
22.15x
P/S ratio:
3.13x
P/B ratio:
3.68x
Volume:
352.6K
Avg. volume:
288.7K
1-year change:
-29.39%
Market cap:
$41.1B
Revenue:
$12.4B
EPS (TTM):
$1.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DSNKY
Daiichi Sankyo Co., Ltd.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | 2.78% | -- | $17.76 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DSNKY
Daiichi Sankyo Co., Ltd.
|
$22.22 | -- | $41.1B | 22.15x | $0.21 | 0% | 3.13x |
|
HLOSF
Healios KK
|
$2.50 | -- | $288.5M | -- | $0.00 | 0% | 392.54x |
|
PPTDF
PeptiDream Inc.
|
$10.95 | -- | $1.4B | 13.79x | $0.00 | 0% | 11.79x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.00 | -- | $452.5M | -- | $0.00 | 0% | 2.34x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$14.18 | $17.76 | $44.8B | 179.95x | $0.32 | 4.66% | 1.53x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DSNKY
Daiichi Sankyo Co., Ltd.
|
10.85% | 0.170 | 3.28% | 1.35x |
|
HLOSF
Healios KK
|
47.23% | -1.205 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.045 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.721 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.563 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DSNKY
Daiichi Sankyo Co., Ltd.
|
$2.3B | $298.2M | 15.69% | 17.17% | 8.78% | -$237.5M |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
Daiichi Sankyo Co., Ltd. vs. Competitors
-
Which has Higher Returns DSNKY or HLOSF?
Healios KK has a net margin of 9.05% compared to Daiichi Sankyo Co., Ltd.'s net margin of -9751.87%. Daiichi Sankyo Co., Ltd.'s return on equity of 17.17% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital DSNKYDaiichi Sankyo Co., Ltd.68.85% $0.17 $12.6B HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About DSNKY or HLOSF?
Daiichi Sankyo Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Daiichi Sankyo Co., Ltd. has higher upside potential than Healios KK, analysts believe Daiichi Sankyo Co., Ltd. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings DSNKYDaiichi Sankyo Co., Ltd.0 0 0 HLOSFHealios KK0 0 0 -
Is DSNKY or HLOSF More Risky?
Daiichi Sankyo Co., Ltd. has a beta of 0.058, which suggesting that the stock is 94.237% less volatile than S&P 500. In comparison Healios KK has a beta of 0.210, suggesting its less volatile than the S&P 500 by 78.954%.
-
Which is a Better Dividend Stock DSNKY or HLOSF?
Daiichi Sankyo Co., Ltd. has a quarterly dividend of $0.21 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daiichi Sankyo Co., Ltd. pays 27.47% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Daiichi Sankyo Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DSNKY or HLOSF?
Daiichi Sankyo Co., Ltd. quarterly revenues are $3.4B, which are larger than Healios KK quarterly revenues of $128.8K. Daiichi Sankyo Co., Ltd.'s net income of $307.3M is higher than Healios KK's net income of $3.8M. Notably, Daiichi Sankyo Co., Ltd.'s price-to-earnings ratio is 22.15x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daiichi Sankyo Co., Ltd. is 3.13x versus 392.54x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DSNKYDaiichi Sankyo Co., Ltd.3.13x 22.15x $3.4B $307.3M HLOSFHealios KK392.54x -- $128.8K $3.8M
-
Which has Higher Returns DSNKY or PPTDF?
PeptiDream Inc. has a net margin of 9.05% compared to Daiichi Sankyo Co., Ltd.'s net margin of -25.38%. Daiichi Sankyo Co., Ltd.'s return on equity of 17.17% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital DSNKYDaiichi Sankyo Co., Ltd.68.85% $0.17 $12.6B PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About DSNKY or PPTDF?
Daiichi Sankyo Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Daiichi Sankyo Co., Ltd. has higher upside potential than PeptiDream Inc., analysts believe Daiichi Sankyo Co., Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings DSNKYDaiichi Sankyo Co., Ltd.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is DSNKY or PPTDF More Risky?
Daiichi Sankyo Co., Ltd. has a beta of 0.058, which suggesting that the stock is 94.237% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.
-
Which is a Better Dividend Stock DSNKY or PPTDF?
Daiichi Sankyo Co., Ltd. has a quarterly dividend of $0.21 per share corresponding to a yield of 0%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daiichi Sankyo Co., Ltd. pays 27.47% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. Daiichi Sankyo Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DSNKY or PPTDF?
Daiichi Sankyo Co., Ltd. quarterly revenues are $3.4B, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. Daiichi Sankyo Co., Ltd.'s net income of $307.3M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, Daiichi Sankyo Co., Ltd.'s price-to-earnings ratio is 22.15x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daiichi Sankyo Co., Ltd. is 3.13x versus 11.79x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DSNKYDaiichi Sankyo Co., Ltd.3.13x 22.15x $3.4B $307.3M PPTDFPeptiDream Inc.11.79x 13.79x $29.3M -$7.4M
-
Which has Higher Returns DSNKY or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 9.05% compared to Daiichi Sankyo Co., Ltd.'s net margin of -24.76%. Daiichi Sankyo Co., Ltd.'s return on equity of 17.17% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital DSNKYDaiichi Sankyo Co., Ltd.68.85% $0.17 $12.6B SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About DSNKY or SOLTF?
Daiichi Sankyo Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Daiichi Sankyo Co., Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Daiichi Sankyo Co., Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings DSNKYDaiichi Sankyo Co., Ltd.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is DSNKY or SOLTF More Risky?
Daiichi Sankyo Co., Ltd. has a beta of 0.058, which suggesting that the stock is 94.237% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.
-
Which is a Better Dividend Stock DSNKY or SOLTF?
Daiichi Sankyo Co., Ltd. has a quarterly dividend of $0.21 per share corresponding to a yield of 0%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daiichi Sankyo Co., Ltd. pays 27.47% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. Daiichi Sankyo Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DSNKY or SOLTF?
Daiichi Sankyo Co., Ltd. quarterly revenues are $3.4B, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Daiichi Sankyo Co., Ltd.'s net income of $307.3M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Daiichi Sankyo Co., Ltd.'s price-to-earnings ratio is 22.15x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daiichi Sankyo Co., Ltd. is 3.13x versus 2.34x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DSNKYDaiichi Sankyo Co., Ltd.3.13x 22.15x $3.4B $307.3M SOLTFNxera Pharma Co., Ltd.2.34x -- $45.8M -$11.3M
-
Which has Higher Returns DSNKY or STMM?
Stemcell Holdings, Inc. has a net margin of 9.05% compared to Daiichi Sankyo Co., Ltd.'s net margin of --. Daiichi Sankyo Co., Ltd.'s return on equity of 17.17% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DSNKYDaiichi Sankyo Co., Ltd.68.85% $0.17 $12.6B STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About DSNKY or STMM?
Daiichi Sankyo Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Daiichi Sankyo Co., Ltd. has higher upside potential than Stemcell Holdings, Inc., analysts believe Daiichi Sankyo Co., Ltd. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DSNKYDaiichi Sankyo Co., Ltd.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is DSNKY or STMM More Risky?
Daiichi Sankyo Co., Ltd. has a beta of 0.058, which suggesting that the stock is 94.237% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock DSNKY or STMM?
Daiichi Sankyo Co., Ltd. has a quarterly dividend of $0.21 per share corresponding to a yield of 0%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daiichi Sankyo Co., Ltd. pays 27.47% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. Daiichi Sankyo Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DSNKY or STMM?
Daiichi Sankyo Co., Ltd. quarterly revenues are $3.4B, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Daiichi Sankyo Co., Ltd.'s net income of $307.3M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Daiichi Sankyo Co., Ltd.'s price-to-earnings ratio is 22.15x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daiichi Sankyo Co., Ltd. is 3.13x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DSNKYDaiichi Sankyo Co., Ltd.3.13x 22.15x $3.4B $307.3M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns DSNKY or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of 9.05% compared to Daiichi Sankyo Co., Ltd.'s net margin of -1.05%. Daiichi Sankyo Co., Ltd.'s return on equity of 17.17% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital DSNKYDaiichi Sankyo Co., Ltd.68.85% $0.17 $12.6B TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About DSNKY or TAK?
Daiichi Sankyo Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.76 which suggests that it could grow by 25.04%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Daiichi Sankyo Co., Ltd., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Daiichi Sankyo Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings DSNKYDaiichi Sankyo Co., Ltd.0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is DSNKY or TAK More Risky?
Daiichi Sankyo Co., Ltd. has a beta of 0.058, which suggesting that the stock is 94.237% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.
-
Which is a Better Dividend Stock DSNKY or TAK?
Daiichi Sankyo Co., Ltd. has a quarterly dividend of $0.21 per share corresponding to a yield of 0%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.66% to investors and pays a quarterly dividend of $0.32 per share. Daiichi Sankyo Co., Ltd. pays 27.47% of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend. Daiichi Sankyo Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios DSNKY or TAK?
Daiichi Sankyo Co., Ltd. quarterly revenues are $3.4B, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. Daiichi Sankyo Co., Ltd.'s net income of $307.3M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, Daiichi Sankyo Co., Ltd.'s price-to-earnings ratio is 22.15x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 179.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daiichi Sankyo Co., Ltd. is 3.13x versus 1.53x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DSNKYDaiichi Sankyo Co., Ltd.3.13x 22.15x $3.4B $307.3M TAKTakeda Pharmaceutical Co., Ltd.1.53x 179.95x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
50
TGL alert for Dec 8
Treasure Global, Inc. [TGL] is up 3.46% over the past day.
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 47.95% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 10.69% over the past day.
